BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Fundamental Analysis
Europe - BIT:1BMRN - US09061G1013 - Common Stock
46.64 EUR
-5.72 (-10.92%)
We assign a fundamental rating of 7 out of 10 to 1BMRN. 1BMRN was compared to 77 industry peers in the Biotechnology industry. 1BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. 1BMRN may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, 1BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year 1BMRN was profitable.
In the past year 1BMRN had a positive cash flow from operations.
1BMRN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years 1BMRN had a positive operating cash flow.
1.2 Ratios
1BMRN's Return On Assets of 7.33% is amongst the best of the industry. 1BMRN outperforms 84.42% of its industry peers.
1BMRN's Return On Equity of 9.04% is amongst the best of the industry. 1BMRN outperforms 84.42% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.16%, 1BMRN belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
1BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 13.10%.
The 3 year average ROIC (3.73%) for 1BMRN is below the current ROIC(9.16%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROIC | 9.16% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 17.76%, 1BMRN belongs to the best of the industry, outperforming 84.42% of the companies in the same industry.
Looking at the Operating Margin, with a value of 24.13%, 1BMRN belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
1BMRN has a Gross Margin of 79.44%. This is in the better half of the industry: 1BMRN outperforms 75.32% of its industry peers.
In the last couple of years the Gross Margin of 1BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
1BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for 1BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, 1BMRN has more shares outstanding
The debt/assets ratio for 1BMRN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.89 indicates that 1BMRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of 1BMRN (5.89) is better than 84.42% of its industry peers.
The Debt to FCF ratio of 1BMRN is 0.96, which is an excellent value as it means it would take 1BMRN, only 0.96 years of fcf income to pay off all of its debts.
1BMRN's Debt to FCF ratio of 0.96 is amongst the best of the industry. 1BMRN outperforms 90.91% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that 1BMRN is not too dependend on debt financing.
1BMRN has a better Debt to Equity ratio (0.10) than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Altman-Z | 5.89 |
ROIC/WACC0.96
WACC9.5%
2.3 Liquidity
1BMRN has a Current Ratio of 5.52. This indicates that 1BMRN is financially healthy and has no problem in meeting its short term obligations.
1BMRN's Current ratio of 5.52 is fine compared to the rest of the industry. 1BMRN outperforms 76.62% of its industry peers.
A Quick Ratio of 3.49 indicates that 1BMRN has no problem at all paying its short term obligations.
1BMRN has a better Quick ratio (3.49) than 66.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 136.84% over the past year.
1BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.36%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
3.2 Future
1BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.94% yearly.
1BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.79% yearly.
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y27.94%
Revenue Next Year11.4%
Revenue Next 2Y10.74%
Revenue Next 3Y9.65%
Revenue Next 5Y7.79%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.37, 1BMRN is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 85.71% of the companies listed in the same industry.
1BMRN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.41.
The Price/Forward Earnings ratio is 12.35, which indicates a correct valuation of 1BMRN.
Based on the Price/Forward Earnings ratio, 1BMRN is valued cheaper than 90.91% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, 1BMRN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.37 | ||
| Fwd PE | 12.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1BMRN is valued cheaper than 84.42% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1BMRN is valued cheaply inside the industry as 87.01% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.99 | ||
| EV/EBITDA | 12 |
4.3 Compensation for Growth
1BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMRN has a very decent profitability rating, which may justify a higher PE ratio.
1BMRN's earnings are expected to grow with 33.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y41.9%
EPS Next 3Y33%
5. Dividend
5.1 Amount
1BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BMRN (9/19/2025, 7:00:00 PM)
46.64
-5.72 (-10.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.66%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner ChangeN/A
Market Cap8.94B
Analysts82.86
Price Target86.99 (86.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.95%
Min EPS beat(2)18.43%
Max EPS beat(2)31.48%
EPS beat(4)4
Avg EPS beat(4)27.84%
Min EPS beat(4)4.22%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)9
Avg EPS beat(12)-4.68%
EPS beat(16)13
Avg EPS beat(16)7.99%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)2.69%
Revenue beat(4)3
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.3%
Revenue beat(16)7
Avg Revenue beat(16)-0.11%
PT rev (1m)-6.6%
PT rev (3m)-6.6%
EPS NQ rev (1m)24.13%
EPS NQ rev (3m)24.13%
EPS NY rev (1m)13.26%
EPS NY rev (3m)13.26%
Revenue NQ rev (1m)0.66%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)1.39%
Revenue NY rev (3m)1.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.37 | ||
| Fwd PE | 12.35 | ||
| P/S | 3.57 | ||
| P/FCF | 16.99 | ||
| P/OCF | 15.05 | ||
| P/B | 1.82 | ||
| P/tB | 1.97 | ||
| EV/EBITDA | 12 |
EPS(TTM)2.29
EY4.91%
EPS(NY)3.78
Fwd EY8.1%
FCF(TTM)2.74
FCFY5.89%
OCF(TTM)3.1
OCFY6.65%
SpS13.06
BVpS25.64
TBVpS23.68
PEG (NY)0.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROCE | 10.92% | ||
| ROIC | 9.16% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 12.43% | ||
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% | ||
| FCFM | 21.02% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Debt/EBITDA | 0.74 | ||
| Cap/Depr | 87.86% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 79.64 | ||
| Cash Conversion | 87.19% | ||
| Profit Quality | 118.38% | ||
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 | ||
| Altman-Z | 5.89 |
F-Score8
WACC9.5%
ROIC/WACC0.96
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y27.94%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
Revenue Next Year11.4%
Revenue Next 2Y10.74%
Revenue Next 3Y9.65%
Revenue Next 5Y7.79%
EBIT growth 1Y301.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.12%
EBIT Next 3Y41.83%
EBIT Next 5Y23.16%
FCF growth 1Y2744.87%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.08%
OCF growth 3Y23.45%
OCF growth 5Y63.99%